FDA Advisory Panel Recommends Six of Seven Peptides for Compounding, Overriding FDA Staff

The peptide question that has hung over telehealth and compounding pharmacies for the past year got its most direct answer yet, and it was not the one the FDA's own scientists asked for. On July 23 and 24, 2026, the agency's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of the seven peptides it reviewed for the list of substances that state-licensed pharmacies may legally compound, even though FDA staff had urged the panel to reject all seven.

This is the outcome of the meeting TeleRanked previewed before the vote. Below are the results peptide by peptide, why the panel split with FDA reviewers, the conflict-of-interest concerns that several news organizations raised, and the important caveat that a committee recommendation is not a final rule.

What the committee decided

The PCAC reviewed seven peptides across two days at the FDA's White Oak campus, each considered in both its free base and acetate forms, for possible inclusion on the Section 503A Bulks List. That list is the roster of bulk drug substances a compounding pharmacy may prepare without an FDA-approved starting product. According to reporting from NPR and TIME on the meeting, the committee voted to recommend six of the seven, and rejected only one. FDA career scientists had recommended against adding any of them, citing limited human data, so the outcome amounted to the committee going against the agency's own review team.

The vote, peptide by peptide

On July 23, the committee took up the first four peptides. Pharmaceutical Executive reported the following tallies:

• BPC-157: recommended, reported at 8 yes, 6 no, 1 abstention.
• KPV: recommended, reported at 8 yes, 6 no, 1 abstention.
• TB-500: recommended, reported at 8 yes, 6 no, 1 abstention.
• MOTS-c: recommended, reported at 7 yes, 5 no, 2 abstentions.

On July 24, the committee reviewed the final three. Per NPR and TIME, the panel voted to recommend Semax and Epitalon, and rejected emideltide, also known as DSIP (delta sleep-inducing peptide). TIME reported the emideltide vote at 6 yes to 7 no, making it the only one of the seven to receive a down vote. Each peptide had been nominated for specific proposed uses (for example, the FDA meeting materials list BPC-157 as nominated in connection with ulcerative colitis and TB-500 with wound healing), but a nomination reflects a proposed use, not evidence that a peptide is safe or effective for it.

Why this went against the FDA's own scientists

In the run-up to the vote, FDA reviewers spoke at length about thin evidence. TIME reported that, on BPC-157, staff said the available evidence weighed against approval, pointing to limited effectiveness data and a single trial involving 46 people, and that for KPV none of the studies were in humans. NPR reported that agency scientists advised the panel to vote no and described the result as a striking rejection of the FDA's stance. FDA officials also stressed a more basic problem: without agreed chemical identity and quality standards for many of these peptides, it is difficult to assess safety at all.

This is a recommendation, not a rule

The most important caveat is procedural. As the FDA's own meeting page states, advisory committees make non-binding recommendations to the FDA, which generally follows them but is not legally bound to do so. TIME reported that the recommendation is not a binding decision and that adding the peptides to the list would still have to go through a lengthy public rulemaking process. Pharmaceutical Executive quoted attorney Dustin Robinson estimating that formal rulemaking typically takes eight to twelve months before pharmacies would have clear legal authority. In other words, the vote signals direction; it does not, by itself, make any of these peptides FDA approved or change what pharmacies may legally compound right now.

Conflict-of-interest questions about the panel

Several news organizations flagged the makeup of the committee. TIME reported that many of the voting members consult with or are employed by companies that could promote or dispense peptides, and named examples including a men's health clinic operator and telehealth companies that had advocated for peptides before the vote. TIME also quoted committee member Dr. Elizabeth Rebello saying she was concerned the panel was responding to market-induced demand rather than a decision grounded in solid science. TeleRanked notes these are concerns raised in reporting about the committee, not findings of wrongdoing.

What it means for patients and telehealth

For telehealth platforms and compounding pharmacies that have built peptide programs, the vote is an encouraging signal but not a green light. If the FDA ultimately follows the recommendation through rulemaking, BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon could gain a clearer legal compounding pathway, while emideltide would remain off the list unless that changes. Until a final rule exists, the legal status of compounding these peptides is unchanged, and products sold outside a licensed pharmacy, including research-chemical vials labeled not for human use, carry the same quality and safety uncertainties the FDA reviewers described.

Limits and what is not settled

Much remains open. The committee's tallies reported here come from news coverage of the meeting; the FDA will publish official meeting minutes and, separately, its own decision. No final rule exists, timelines are estimates, and the FDA can depart from the committee's advice. This article is general information for a telehealth audience, not medical advice. It is not an endorsement of any peptide, and none of these substances is FDA approved for the uses discussed. Anyone considering peptide therapy should talk with a licensed clinician and rely on primary FDA documents rather than marketing claims.